FairJourney Biologics and IONTAS sign agreement with Pandion Therapeutics to discover antibodies

FairJourney Biologics S.A (FJB) and IONTAS Limited (IONTAS), leaders in the discovery and optimization of VHH and fully human antibodies, today announced they have signed an agreement to discover antibodies with Pandion Therapeutics (Pandion). The partnership will harness both FJB and IONTAS’ proprietary antibody libraries and technology platforms to investigate novel therapeutic targets for autoimmune and inflammatory diseases.

FairJourney Biologics and IONTAS sign agreement with Pandion Therapeutics to discover antibodies
FairJourney Biologics laboratory

Pandion focuses on the development of innovative modular therapeutics using its TALON™ (Therapeutic Autoimmune reguLatOry proteiN) drug design and discovery platform. The TALON effector modules are based on immunomodulatory molecules that act as regulatory control points within the immune system. In conjunction with a tissue-specific targeting moiety, the effectors create novel bifunctional molecules for the treatment of autoimmune and inflammatory diseases.

Under the terms of the agreement, Pandion will access the novel libraries and platform technologies provided by FJB and IONTAS. A dedicated FJB/IONTAS FTE will be assigned to the project with the aim of discovering diverse panels of novel target binders for use within the TALON platform. The Agreement extends an existing relationship between the companies and gives Pandion the option to use standard phage display or mammalian display as the engines for the discovery of next generation antibodies.

Our teams have gained considerable experience in antibody discovery for use in generating mono-specific and bi-specific therapeutics. We now have a pipeline of undisclosed therapeutic partnerships nearing clinical research. We look forward to continuing our relationship with Pandion and applying our experience and expertise to generate a diverse set of antibodies for further study.”

Dr António Parada, CEO at FairJourney Biologics and IONTAS

Our TALON platform leverages natural immune regulatory mechanisms, to re-balance immune responses and ultimately advance discovery into novel treatments for autoimmune and inflammatory diseases. The experience in antibody discovery shared by FJB and IONTAS, together with their unique library of target binders, makes them ideal partners as we focus on successfully progressing these transformational therapies to patients in need.”

Dr Hussam Shaheen, Director of Antibody Discovery and Engineering at Pandion Therapeutics


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Vaccine candidate spurs elusive type of broadly neutralizing HIV antibodies